Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

• Status: RECRUITING
• Trial end date: 2026-06-30

Summary

This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.

• Phase: PHASE1

Details

• Lead Sponsor: Zhejiang Doer Biologics Co., Ltd.
• Treatments: Capecitabine; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin